AAV gene therapy

Cystinuria

estimated prevalence

30,000

Disease

Cystinuria

Genetic Source

SLC3A1, SLC7A9

Clinical Phase

Pre-clinical

Modality

gene therapy icon gene therapy

Cystinuria is a renal disease characterized by severe kidney stones and is caused by mutations in either of two solute carrier genes- SLC3A1 or SLC7A9. BridgeBio is developing an investigational adeno-associated virus (AAV) gene therapy to potentially deliver a functional copy of the SLC3A1 gene directly to the cells of the kidney involved in amino acid reabsorption via the transport complex. If successful, BridgeBio hopes to restore the kidney’s ability to form a functional amino acid transport system, thereby correcting the hyperexcretion of urinary cystine that causes stone formation in cystinuria. There are currently no approved therapies for cystinuria other than limiting sodium and protein intake.

our science

our science icon icon

our approach icon icon

patient resources icon icon